LT2868315T - Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai - Google Patents

Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai

Info

Publication number
LT2868315T
LT2868315T LTEP14188334.8T LT14188334T LT2868315T LT 2868315 T LT2868315 T LT 2868315T LT 14188334 T LT14188334 T LT 14188334T LT 2868315 T LT2868315 T LT 2868315T
Authority
LT
Lithuania
Prior art keywords
lyophilates
lyophilization
methods
improved formulations
formulations
Prior art date
Application number
LTEP14188334.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Martin Sven Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of LT2868315T publication Critical patent/LT2868315T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP14188334.8T 2007-12-04 2008-12-03 Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai LT2868315T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99224107P 2007-12-04 2007-12-04

Publications (1)

Publication Number Publication Date
LT2868315T true LT2868315T (lt) 2017-09-25

Family

ID=40718143

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14188334.8T LT2868315T (lt) 2007-12-04 2008-12-03 Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai

Country Status (14)

Country Link
US (6) US8277845B2 (show.php)
EP (2) EP2224913B1 (show.php)
JP (5) JP5812318B2 (show.php)
CN (1) CN101932308B (show.php)
CA (3) CA3123813C (show.php)
CY (1) CY1119256T1 (show.php)
DK (1) DK2868315T3 (show.php)
ES (1) ES2638977T3 (show.php)
HR (1) HRP20171223T1 (show.php)
LT (1) LT2868315T (show.php)
PL (1) PL2868315T3 (show.php)
PT (1) PT2868315T (show.php)
SI (1) SI2868315T1 (show.php)
WO (1) WO2009073711A1 (show.php)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932308B (zh) * 2007-12-04 2014-11-05 治疗医药股份有限公司 改良的配制剂和用于冻干的方法及由此提供的冻干物
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
US20140287998A1 (en) * 2011-12-09 2014-09-25 Enject, Inc. Glucagon formulations
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
PL4289948T3 (pl) * 2012-05-25 2025-06-02 The Regents Of The University Of California Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
CA2929821A1 (en) 2013-11-06 2015-05-14 Aeromics, Inc. 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits
WO2015134906A1 (en) * 2014-03-07 2015-09-11 Endologix, Inc. Forming hydrogels and materials therefor
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
ES2927482T3 (es) 2015-05-29 2022-11-07 Univ Maryland Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales
IL258509B2 (en) 2015-10-07 2023-04-01 Biogen Chesapeake Llc Methods for treating injuries or conditions related to edema in the central nervous system
US20170320862A1 (en) * 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
KR102646250B1 (ko) 2016-07-29 2024-03-11 레메디 파마슈티칼즈, 인크. Sur1-trpm4 통로 저해제를 이용하는 의학적 치료 방법
CN108210501B (zh) 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
CN110753667B (zh) 2017-06-30 2021-08-31 村田机械株式会社 搬运系统以及搬运方法
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法
WO2022187567A2 (en) * 2021-03-04 2022-09-09 Biogen Chesapeake Llc Low-sorbing glyburide formulation and methods
WO2022195115A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating subacute cutaneous lupus erythematosus
CN113274361B (zh) * 2021-06-08 2022-05-06 吉林津升制药有限公司 一种烟酰胺冻干粉针剂及其制备方法
CN119173250A (zh) * 2022-03-03 2024-12-20 瑞迪制药有限公司 低吸附格列本脲试剂盒、制剂和方法
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB9003185D0 (en) * 1990-02-13 1990-04-11 Ici Plc Pharmaceutical compositions
DE69306755T2 (de) 1992-01-21 1997-04-10 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
PL316995A1 (en) * 1994-04-25 1997-03-03 Kyowa Hakko Kogyo Kk Method of stabilising the dx-52-1 compound and freeze dried compositions thereof
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
KR101042660B1 (ko) * 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
SK284511B6 (sk) 1997-07-29 2005-05-05 Pharmacia & Upjohn Company Samoemulgujúce formulácie pre lipofilné zlúčeniny
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AU8822598A (en) * 1998-05-29 1999-12-20 Biogen, Inc. Recombinant human interferon beta-1a (ifn-beta-1a) formulation
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
JP3956654B2 (ja) 2000-06-29 2007-08-08 小野薬品工業株式会社 Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
AU2002306461A1 (en) 2001-03-28 2002-10-15 Rheologics, Inc. In vivo delivery methods and compositions
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP2005501817A (ja) 2001-06-12 2005-01-20 アクティブ パス ファーマシューティカルズ， インコーポレイテッド β−アミロイド産生を調節する化合物、組成物および方法
CA2682251A1 (en) * 2001-07-17 2003-01-30 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE10341414A1 (de) 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
CA2566873C (en) 2004-05-20 2013-02-12 Diamedica Inc. Use of drug combinations for treating insulin resistance
CA2580606A1 (en) 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
US20060183803A1 (en) 2005-02-17 2006-08-17 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of assorted health problems
US7659281B2 (en) 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
RS52657B (sr) 2006-09-29 2013-06-28 Infa S.A. Sistem pakovanja za farmaceutske smeše i komplet za intravensku primenu
CN101932308B (zh) * 2007-12-04 2014-11-05 治疗医药股份有限公司 改良的配制剂和用于冻干的方法及由此提供的冻干物

Also Published As

Publication number Publication date
HRP20171223T1 (hr) 2017-11-03
CA3123813A1 (en) 2009-06-11
CN101932308A (zh) 2010-12-29
CA2707484A1 (en) 2009-06-11
US10426729B2 (en) 2019-10-01
DK2868315T3 (en) 2017-09-04
JP6603762B2 (ja) 2019-11-06
US10117834B2 (en) 2018-11-06
CA3240562A1 (en) 2009-06-11
EP2868315B1 (en) 2017-05-31
WO2009073711A1 (en) 2009-06-11
ES2638977T3 (es) 2017-10-24
US20150141516A1 (en) 2015-05-21
EP2224913B1 (en) 2014-10-15
CA2707484C (en) 2021-08-10
JP6084639B2 (ja) 2017-02-22
SI2868315T1 (sl) 2017-10-30
PL2868315T3 (pl) 2018-06-29
US20130245069A1 (en) 2013-09-19
US20100273886A1 (en) 2010-10-28
US8277845B2 (en) 2012-10-02
JP2015134763A (ja) 2015-07-27
JP2011505424A (ja) 2011-02-24
EP2224913A1 (en) 2010-09-08
US10869835B2 (en) 2020-12-22
US20190099372A1 (en) 2019-04-04
PT2868315T (pt) 2017-09-04
US20210244669A1 (en) 2021-08-12
JP6377189B2 (ja) 2018-08-22
US20200093747A1 (en) 2020-03-26
JP5812318B2 (ja) 2015-11-11
JP2018197244A (ja) 2018-12-13
JP2017128569A (ja) 2017-07-27
CA3123813C (en) 2024-10-08
US8858997B2 (en) 2014-10-14
CY1119256T1 (el) 2018-02-14
JP2020007334A (ja) 2020-01-16
EP2868315A1 (en) 2015-05-06
JP6866438B2 (ja) 2021-04-28
CN101932308B (zh) 2014-11-05
EP2224913A4 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
ZA201203709B (en) Immunogenic compositions and methods
IL200108A0 (en) Solid preparation comprising alogliptin and pioglitazone
SG10201501296SA (en) Lyophilized therapeutic peptibody formulations
PT2205336T (pt) Sistema e método para produzir formulações secas
IL197781A0 (en) Lyophilization methods and apparatuses
EP2449102A4 (en) ARGINASE FORMULATIONS AND METHODS
ZA200808489B (en) Nicotine-carrier vaccine formulation
EP2111215A4 (en) MATERIALS AND METHOD FOR THE ADMINISTRATION OF ANTIOXIDANTS IN THE SKIN
IL211670A0 (en) Therapeutic protein formulations
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
EP2160183A4 (en) QUETIPIN EXTENDED FORMULATIONS WITH EXTENDED RELEASE AND METHOD OF MANUFACTURING THEREOF
GB0719202D0 (en) Compositions and methods for the skin and hair
PL2320739T3 (pl) Kompozycje farmaceutyczne i sposoby ich stabilizowania
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
PL2207567T3 (pl) Preparat immunogenny
EP2300018A4 (en) PAEONIFLORINE PREPARATIONS AND THEIR USE OF FAT REDUCTION
GB0719248D0 (en) Compounds and methods for pharmaceutical use
ZA201003524B (en) Injectable meclizine formulations and methods
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
ZA201008384B (en) Lasalocid compositions and methods
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0725007D0 (en) Carcino-immune therapeutic animal gland extract
GB0713093D0 (en) Pharmaceutical formulations